Physicians' Academy for Cardiovascular Education

Expanding evidence on SGLT2i: Where are we now and what can we expect?

Listen to the podcast
10' education - July 21, 2022 - Prof. Scott Solomon, MD - Boston, MA, USA

Video navigation menu

  • Unanswered questions with SGLT2 inhibitors 00:22
  • DELIVER study design 02:03
  • Baseline characteristics of DELIVER compared with other HFpEF trials 05:01
  • What DELIVER can deliver 10:25


Show transcript

Educational information

This lecture by prof. Solomon was part of the EBAC-accredited symposium "When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options" held during the ESC Heart Failure 2022 congress.


Scott D. Solomon, MD is the Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School and directs the Clinical Trials Outcomes Center at Brigham and Women’s Hospital.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: